老年冠心病患者阿司匹林抵抗的临床观察(2)
2 Antiplatelet Triallist’s Collaboration.Collaborative overview of randomized trial of antiplatelet therapy2 Ⅱ.Maintenance of vascular graft or arterial patency by antiplatelet therapy.BMJ,1994,308:159-168.
3 Antiplatelet Trialist’s Collaboration Collaborative overview of randomized trial of antiplatelet therapy2 Ⅲ.Reduction in venous thrombosis and pulmonary em2 bolism by antiplatelet prophylaxis among surgical and medical patients.BMJ,1994,308:235-246.
4 Eikelboom JW,Hirs HJ,WeitzJI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105 ( 14 ):1650-1655.
5 Gum PA,Kottke-Marchant K,Poggio ED,et al.Profile and Prevalence of Aspirin Resistance in Patients WithCardiovascular Disease.Am J Cardiol,2001,88(3):230-235.
6 Helgason CM,Bolion KM,Hoff JA,et al.Development of aspiri resistanceinpersonswithpreviousischemi stroke.Stroke,1994,25:2331.
7 Weber AA,Zimmermann KC,Meyer2Kirchrat h J,et al.Cyclooxygenase22 in human platelet s as a possible factor in aspirin resistance.Lancet,1999,353 (9156):900.
8 Vane JR,Bakhle YS,Botting RM.Cyclooxygenases 1 and 2.Ann Rev Pharmacol Toxicol,1998,38 (1):97-120.
9 Macchi L,Christiaens L,Brabant S,et al.Resistance to aspirin in vitro is associated wit h increased platelet sensitivity to adenosine diphosphate.Thromb RES,2002,107(122):45-49., 百拇医药(王春生 王晓岩)
3 Antiplatelet Trialist’s Collaboration Collaborative overview of randomized trial of antiplatelet therapy2 Ⅲ.Reduction in venous thrombosis and pulmonary em2 bolism by antiplatelet prophylaxis among surgical and medical patients.BMJ,1994,308:235-246.
4 Eikelboom JW,Hirs HJ,WeitzJI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105 ( 14 ):1650-1655.
5 Gum PA,Kottke-Marchant K,Poggio ED,et al.Profile and Prevalence of Aspirin Resistance in Patients WithCardiovascular Disease.Am J Cardiol,2001,88(3):230-235.
6 Helgason CM,Bolion KM,Hoff JA,et al.Development of aspiri resistanceinpersonswithpreviousischemi stroke.Stroke,1994,25:2331.
7 Weber AA,Zimmermann KC,Meyer2Kirchrat h J,et al.Cyclooxygenase22 in human platelet s as a possible factor in aspirin resistance.Lancet,1999,353 (9156):900.
8 Vane JR,Bakhle YS,Botting RM.Cyclooxygenases 1 and 2.Ann Rev Pharmacol Toxicol,1998,38 (1):97-120.
9 Macchi L,Christiaens L,Brabant S,et al.Resistance to aspirin in vitro is associated wit h increased platelet sensitivity to adenosine diphosphate.Thromb RES,2002,107(122):45-49., 百拇医药(王春生 王晓岩)